Highbridge Capital Management’s AstraZeneca AZN Stock Holding History

Highbridge Capital Management’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-7,500	Closed	-$525K	–	917
2018 Q1	$525K	Buy	+7,500	New	+$520K	0.01%	680
2017 Q3	–	Sell	-50,000	Closed	-$3.41M	–	1522
2017 Q2	$3.41M	Buy	+50,000	New	+$3.27M	0.05%	363
2016 Q3	–	Sell	-139,848	Closed	-$8.44M	–	1310
2016 Q2	$8.44M	Buy	+139,848	New	+$8.12M	0.14%	190

Other funds holding AZN

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

EIP

Epoch Investment Partners New York $17.6B AUM 34.17% 1-Year Est. Return

Highbridge Capital Management's AZN Position: Q2 2018 in Review

Highbridge Capital Management sold out of AstraZeneca (AZN) in Q2 2018, closing a stake of 7,500 shares — an estimated $525K sold.

Highbridge Capital Management first reported a position in AZN in Q2 2016 and held it in 3 quarters. The position peaked at $8.44M in Q2 2016. 530 funds tracked by Wall St. Rank hold AZN as of Q2 2018.

Highbridge Capital Management reported no remaining AstraZeneca position as of Q2 2018 after selling out during the quarter.
Highbridge Capital Management sold 7,500 AstraZeneca shares in Q2 2018, an estimated $525K.
Highbridge Capital Management first reported a position in AstraZeneca in Q2 2016 and held it in 3 quarters.
Highbridge Capital Management's AstraZeneca position peaked at $8.44M in Q2 2016.
530 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2018.

Based on Highbridge Capital Management's 13F filing for Q2 2018, filed 14 Aug 2018.